-
Mashup Score: 6FDA Approves Alectinib for Early-Stage ALK+ NSCLC - 22 day(s) ago
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The phase 1/2 WU-KONG1 findings support the breakthrough therapy designation for sunvozertinib for those with EGFR-mutated non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Pembrolizumab/MK-1084 Combo Is the Focus of Phase 3 Trial in KRAS G12C+ Metastatic NSCLC - 1 month(s) ago
MK-1084 previously demonstrated manageable safety and preliminary activity in non–small cell lung cancer harboring KRAS G12C mutations as part of a phase 1 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 1 month(s) ago
The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 40ESMO Guidelines: Real World Cases - Webinar Series: Non-Oncogene-Addicted Metastatic Non-small-cell Lung Cancer (NSCLC) 2024 - 1 month(s) ago
ESMO Guidelines: Real World Cases – Webinar Series: Non-Oncogene-Addicted Metastatic Non-small-cell Lung Cancer (NSCLC) 2024Chair: Antonio PassaroSpeakers: Hongcheng Zhu, Solange Peters, Jaafar Bennouna
Source: oncologypro.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16NSCLC Clinical Case Simulations for Practicing Oncologists - 1 month(s) ago
Welcome to our interactive training module. Please select from below to
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The phase 3 KEYLYNK-006 trial did not meet the primary end points of progression-free and overall survival in patients with metastatic nonsquamous non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2About the Continued Evaluation of MK-1084 for NSCLC and More - 2 month(s) ago
Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
.@US_FDA approves alectinib for the adjuvant treatment of patients with ALK-positive NSCLC with tumors that are at least 4 cm or node-positive, as detected by an FDA-approved test. #NSCLC | @FDAOncology https://t.co/nXvufdYEBq https://t.co/ub6RfoQ1Q6